The European Parliament Approves the World's First Comprehensive AI Legislation
On March 13, 2024, during its plenary session, the European Parliament approved the Proposal for a Regulation of the European Parliament and of the Council Establishing Harmonised Rules on Artificial Intelligence (AI Act). This approval came after the AI Act was signed by the Committee of Permanent Representatives (Coreper) on February 2, 2024, and received backing from both the Internal Market (IMCO) and the Civil Liberties, Justice, and Home Affairs (LIBE) Committees on February 13, 2024.
The Parliament has stated that the AI Act is pending a final review by legal and linguistic experts and is anticipated to be officially passed before the current legislative term ends, utilizing the correction process known as the corrigendum procedure. Additionally, the AI Act requires formal approval from the Council of the European Union. The legislation will become fully enforceable 24 months after it takes effect, with the following exceptions:
- Prohibitions on certain practices will be effective six months after enactment;
- Implementation of codes of practice will start nine months after enactment;
- Rules for general-purpose AI, including governance, will be implemented 12 months after enactment;
- Requirements for high-risk systems will come into effect 36 months after enactment.
Click here to read the press release
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
The European Health Data Space overcomes its final obstacle in Parliament
iliomad is deligthed to have supported the ICM - Institut du Cancer de Montpellier in their CNIL's authorization process
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study. The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022. The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer. We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
